Skip to main content
. 2022 Jul 13;10(7):e004589. doi: 10.1136/jitc-2022-004589

Figure 3.

Figure 3

MHC-I-deficient tumors are sensitized to CD47/SIRPα blockade. The inhibitory receptor LILRB1, which binds surface MHC I, shows synergy with other inhibitory receptor pathways, including the CD47/SIRPα axis. Figure created with BioRender.com. CD47, cluster of differentiation 47; LILRB1, Leukocyte immunoglobulin-like receptor subfamily B member 1; MHC-I, major histocompatibility complex I; SIRPα, signal regulatory protein alpha.